Last reviewed · How we verify
NCT06310161
Light Therapy in End Stage Kidney Disease
NA trial testing Bright light in End Stage Renal Disease in 60 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 February 2026 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Bright light
- Dim Light
Conditions studied
- End Stage Renal Disease — all drugs for End Stage Renal Disease →
Sponsor
University of Pennsylvania
Who can join
18 and older, any sex, with End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to test light therapy in patients with end stage kidney disease who are receiving hemodialysis. The main aim is to determine if light therapy decreases fatigue severity. Participants will receive light therapy using special glasses for one hour during the dialysis sessions for four weeks of treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06310161
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bright light
Trials testing the same drug.
- NCT06292819 — Effects of Photobiomodulation on Insomnia in the Elderly: Clinical Trials of Phototherapy Devices · NA · completed
Other recruiting trials for End Stage Renal Disease
Currently open trials in the same condition.
- NCT06257134 — Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients. · NA · recruiting
- NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
- NCT06422871 — PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis · recruiting
- NCT06861816 — Ventilatory Functions and Physical Intolerance in ESRD Adolescents: Response to Program of Walking With Dogs · NA · recruiting
- NCT06326905 — CAPABLE Transplant · NA · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06310161 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 27 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06310161.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing